Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology

The coronary pressure wire is used for physiological assessment of the coronary vasculature increasingly frequently in clinical practice. Fractional flow reserve (FFR) can now be used to assess lesion severity in a variety of anatomical situations. Increasingly, the coronary pressure wire is being used to interrogate the coronary microvasculature. Coronary flow reserve (CFR) and Index of microcirculatory resistance (IMR) require hyperaemia to accurately assess thermodilution—derived mean transit times, and pressure derived collateral flow index (CFIp) is calculated from coronary wedge pressure and aortic pressure at hyperaemia. In addition, coronary flow velocity as assessed by a coronary Doppler flow wire needs appropriate induction of hyperaemia. However, the majority of this article will however focus on hyperaemia induction for pressure wire studies particularly FFR. Significant clinical decisions are made as a result of FFR readings, therefore it is imperative that they are carried out correctly. Maximal coronary hyperaemia is essential in producing accurate, reproducible measurements. This article focuses on the pharmacological agents that can be used for this purpose, discusses which agents can be used in specific situations, and briefly addresses the future of pharmacological stress in the catheter laboratory. © 2008 Wiley‐Liss, Inc.

[1]  G. Amit,et al.  Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. , 2006, American heart journal.

[2]  C. Tribouilloy,et al.  Transthoracic coronary flow velocity reserve assessment: comparison between adenosine and dobutamine. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[3]  R. Foale,et al.  Dobutamine-induced hyperaemia inversely correlates with coronary artery stenosis severity and highlights dissociation between myocardial blood flow and oxygen consumption , 2006, Heart.

[4]  W. Hau.  Routine pressure-derived fractional flow reserve guidance: from diagnostic to everyday practice. , 2006, The Journal of invasive cardiology.

[5]  M. Cerqueira.  Advances in pharmacologic agents in imaging: New A2A receptor agonists , 2006, Current cardiology reports.

[6]  R. Hendel,et al.  Initial clinical experience with regadenoson, a novel selective A 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging , 2005 .

[7]  D. Miller.  Impact of selective adenosine A2A receptor agonists on cardiac imaging feeling the lightning, waiting on the thunder. , 2005, Journal of the American College of Cardiology.

[8]  U. Siebert,et al.  The validation of fractional flow reserve in patients with coronary multivessel disease: a comparison with SPECT and contrast-enhanced dobutamine stress echocardiography , 2005, Zeitschrift für Kardiologie.

[9]  O. Rimoldi,et al.  Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Uwe Siebert,et al.  Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve? , 2004, American heart journal.

[11]  M. Cerqueira.  The future of pharmacologic stress: selective A2A adenosine receptor agonists. , 2004, The American journal of cardiology.

[12]  M. Kern,et al.  Coronary Hyperemic Dose Responses of Intracoronary Sodium Nitroprusside , 2004, Circulation.

[13]  James R. Johnson,et al.  Randomized, Controlled Dose-Ranging Study of the Selective Adenosine A2A Receptor Agonist Binodenoson for Pharmacological Stress as an Adjunct to Myocardial Perfusion Imaging , 2004, Circulation.

[14]  A. Iskandrian,et al.  Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. , 2004, The American journal of cardiology.

[15]  R. Lopez-Palop,et al.  Adequate intracoronary adenosine doses to achieve maximum hyperaemia in coronary functional studies by pressure derived fractional flow reserve: a dose response study , 2003, Heart.

[16]  B. Murtagh,et al.  Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. , 2003, American heart journal.

[17]  W. Wijns,et al.  Intracoronary and Intravenous Adenosine 5′-Triphosphate, Adenosine, Papaverine, and Contrast Medium to Assess Fractional Flow Reserve in Humans , 2003, Circulation.

[18]  U. Siebert,et al.  Coronary Pressure Measurement After Stenting Predicts Adverse Events at Follow-Up: A Multicenter Registry , 2002, Circulation.

[19]  A. Jeremias,et al.  Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements. , 2000, American heart journal.

[20]  園田 信成.  Safety and optimal dose of intracoronary adenosine 5'-triphosphate for the measurement of coronary flow reserve , 1998 .

[21]  M. Phelps,et al.  Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. , 1996, Circulation.

[22]  J. Bech,et al.  Comparison of intravenous adenosine to intracoronary papaverine for calculation of pressure-derived fractional flow reserve. , 1996, Catheterization and cardiovascular diagnosis.

[23]  M. Takeuchi,et al.  Intracoronary papaverine induced myocardial lactate production in patients with angiographically normal coronary arteries. , 1996, Catheterization and cardiovascular diagnosis.

[24]  M. Winniford,et al.  The effect of aminophylline on pharmacological stress with intravenous adenosine. , 1996, American journal of cardiac imaging.

[25]  N. Pandian,et al.  Accurate quantitation of right ventricular size and function by voxel-based 3-dimensional echocardiography in patients with normal and abnormal ventricles (3DE): Comparison with magnetic resonance imaging , 1996 .

[26]  P. H. van der Voort,et al.  Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. , 1995, Circulation.

[27]  H. Sugihara,et al.  Intracoronary adenosine 5'-triphosphate as an alternative to papaverine for measuring coronary flow reserve. , 1994, The American journal of cardiology.

[28]  T. Inoue,et al.  QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine. , 1994, Cardiology.

[29]  A. Takeshita,et al.  Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. , 1993, The New England journal of medicine.

[30]  M. Kern,et al.  The effects of ionic and nonionic radiographic contrast media on coronary hyperemia in patients during coronary angiography. , 1992, American heart journal.

[31]  D. Harrison,et al.  Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. , 1991, Biochemical pharmacology.

[32]  H. De Geest,et al.  Torsades de pointes after intracoronary papaverine. , 1991, European heart journal.

[33]  S. Port,et al.  Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. , 1991, Circulation.

[34]  R. Wilson,et al.  Effects of adenosine on human coronary arterial circulation. , 1990, Circulation.

[35]  M. Kern,et al.  Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve. , 1990, Catheterization and cardiovascular diagnosis.

[36]  J. Ruskin,et al.  Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. , 1989, The American journal of cardiology.

[37]  R. Wilson,et al.  Serious ventricular dysrhythmias after intracoronary papaverine. , 1988, American Journal of Cardiology.

[38]  R. Zelis,et al.  Serious Ventricular Dysrhythmias After Intracoronary Papaverine , 1988 .

[39]  J. Hodgson,et al.  Superiority of intracoronary papaverine to radiographic contrast for measuring coronary flow reserve in patients with ischemic heart disease. , 1987, American heart journal.

[40]  R. Wilson,et al.  Intracoronary papaverine: an ideal coronary vasodilator for studies of the coronary circulation in conscious humans. , 1986, Circulation.

[41]  C. Higgins,et al.  Comparative effects of ionic anc nonionic contrast materials on coronary and peripheral blood flow. , 1982, Investigative radiology.

[42]  A. Gosselin,et al.  Sodium nitroprusside as a coronary vasodilator in man , 1977 .

[43]  R. Patterson,et al.  Evidence for an Adenosine Receptor on the Surface of Dog Coronary Myocytes , 1976, Circulation research.

[44]  A. Gosselin,et al.  Sodium nitroprusside as a coronary vasodilator in man. I. Effect of intracoronary sodium nitroprusside on coronary arteries, angina pectoris, and coronary blood flow. , 1976, American heart journal.